UVA 370 NM PHOTOTHERAPY OF ATOPIC DERMATITIS


如何引用文章

全文:

详细

The UVA (l = 370 nm) mechanism of action and its use in atopic dermatitis, therapeutic modes, indications and contraindications are discussed. The authors present the results of treatment of 24 patients by UVA 370 nm phototherapy. The patients were distributed into 2 groups. Group 1 consisted of 14 patients with moderate atopic dermatitis, receiving UVA monotherapy. Group 2 consisted of 10 patients with moderate to severe atopic dermatitis, receiving UVA phototherapy in combination with conventional therapy (antihis taminic drugs, adsorbents, emollients). The SCORAD index of group 1 patients reduced from 15.6 before therapy to 3.4 after therapy, in group 2 from 28.6 to 7.5, respectively. No side effects, except moderate dry ness of the skin, were recorded. The data indicated high efficiency and safety of the method.

作者简介

Ol'ga Olisova

I.M.Setchenov First Moscow State Medical University

доктор мед. наук, профессор Moscow, Russia

Vladimir Vladimirov

Institute of Dermatology and Cosmetology

доктор мед. наук, профессор Moscow, Russia

Ekaterina Murakhovskaya

I.M.Setchenov First Moscow State Medical University

Email: ekaterina_49@mail.ru
аспирант Moscow, Russia

参考

  1. Hänel K.H., Cornelissen C., Lüscher B., Baron J.M. Cytokines and the skin barrier. Int. J. Mol. Sci. 2013; 14(4): 6720—45.
  2. Sokolovskij E.V., Monahov K.N., Holodilova N.A. Atopic dermatitis and hand exema betametazone intermittent therapy. Russian Journal of Skin and Sexually Transmitted Diseases. 2009; 3: 16—21. (Intermittirujushhaja terapija betametazonom atopicheskogo dermatita i jekzemy kistej. Rossijskij zhurnal kozhnyh i venericheskih boleznej). 2009; 3: 16—21
  3. Kubanova A.A., Kisina V.I., eds. Rational drug therapy diseases of the skin and sexually transmitter infections. Guide for practician (Racional’naja farmakoterapija zabolevanij kozhi i infekcij, peredavaemyh polovym putem: Rukovodstvo dlja praktikujushhih vrachej). Moscow: Litterra; 2005.
  4. Volkova E.N. Atopic dermatitis (Atopicheskij dermatit). Lechashhij vrach. 2006; 9: 14—8.
  5. Simon J.C., Pfieger D., Schöpf E. Recent advances in phototherapy. Eur. J. Dermatol. 2000; 10(8): 642—5.
  6. Mutzhas M.F., Holzle E., Hofmann C., Plewig.G. A new apparatus with high radiation energy between 320—460 nm: physical description and dermatological applications. J. Invest. Dermatol. 1981; 76(1): 42—7.
  7. Krutmann J., Czech W., Diepgen T., Niedner R., Kapp A., Schopf E. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J. Am. Acad. Dermatol. 1992; 26(2, Pt 1): 225—30.
  8. Krutmann J., Schöpf E. High-dose-UVA1 phototherapy: a novel and highly effective approach for the treatment of acute exacerbation of atopic dermatitis. Acta Derm. Venereol. (Stockh.). 1992; 176(Suppl.): 120—2.
  9. McGrath H.Jr. Ultraviolet A1 (340—400 nm) irradiation and systemic lupus erythematosus. J. Investig. Dermatol. Symp. Proc. 1999; 4(1): 79—84.
  10. Szegedi A., Simics E., Aleksza M., Horkay I., Gaal K., Sipka S. Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005; 44(7): 925—31.
  11. Breuckmann F., Stuecker M., Altmeyer P., Kreuter A. Modulation of endothelial dysfunction and apoptosis: UVA1-mediated skin improvement in systemic sclerosis. Arch. Dermatol. 2004; 296(5): 235—9.
  12. Morita A., Kobayashi K., Isomura I., Tsuji T., Krutmann J. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J. Am. Acad. Dermatol. 2000; 43(4): 670—4.
  13. Tewari A., Garibaldinos T., Lai-Cheong J., Groves R., Sarkany. R., Branislav Novakovic L. Successful treatment of microstomia with UVA1 phototherapy in systemic sclerosis. Photodermatol. Photoimmunol. Photomed. 2011; 27(2): 113—4.
  14. Volnuhin V.A., Muradjan N.L., Vybornova O.V., Katunina O.R., Borovaja O.V., Volkov A.V. UVA1 therapy of morphea (UFA-1 terapija bol’nyh ogranichennoj sklerodermiej). Vestnik dermatologii i venerologii. 2007; 6: 4—8.
  15. Camacho N.R., Sanchez J.E., Martin R.F., Gonzalez R.F., Sanches J.L. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J. Am. Acad. Dermatol. 2001; 45(5): 697—9.
  16. Kerscher M., Volkenandt M., Gruss C., Reuther T., von Kobyletzki G., Freitag M. Low-dose UVA phototherapy for treatment of localized scleroderma. J. Am. Acad. Dermatol. 1998; 38(1): 21—6.
  17. Kreuter A., Hyun J., Stucker M., Sommer A., Altmeyer P., Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J. Am. Acad. Dermatol. 2006; 54(3): 440—7.
  18. Andres C., Kollmar A., Mempel M., Hein R., Ring J., Eberlein B. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br. J. Dermatol. 2010; 162(2): 445—7.
  19. Tzaneva S., Seeber A., Schwaiger M., Honigsmann H., Tanew A. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J. Am. Acad. Dermatol. 2001; 45(4): 503—7.
  20. El-Zawahry B.M., Bassiouny D.A., Sobhi R.M., Abdel-Aziz E., Zaki N.S., Habib D.F., Shahin D.M. A comparative study on efficacy of UVA1 vs. narrowband UVB phototherapy in the treatment of vitiligo. Photodermatol. Photoimmunol. Photomed. 2012; 28(2): 84—90.
  21. Rombold S., Lobisch K., Katzer K., Grazziotin T.C., Ring J., Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol. Photoimmunol. Photomed. 2008; 24(1): 19—23.
  22. Levi A., Ingber A., Enk C.D. Ultraviolet A1 exposure is crucial in the treatment of prurigo nodulalis using a ultraviolet A1/topical steroid combination regimen. Photodermatol. Photoimmunol. Photomed. 2011; 27(1): 55—6.
  23. Zane C., Leali C., Airo P., De Panfilis G., Pinton P.C. “High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J. Am. Acad. Dermatol. 2001; 44(4): 629—33.
  24. Plettenberg H., Stege H., Megahed M., Ruzicka T., Hosokawa Y., Morita A. Ultraviolet A1 (340—400 nm) phototherapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 1999; 41(1): 47—50.
  25. Bakulev L.A., Platonova A.N., Rasskazov Ja.A., Alipov N.V. Clinical effectiveness of UVA1 in treatment of chronic dermatosis (Klinicheskaja jeffektivnost’ primenenija UFA 1-terapii v kompleksnom lechenii hronicheskih dermatozov). Vestnik dermatologii i venerologii. 2012; 4: 64—9.
  26. Polderman M.C., Wintzen M., le Cessie S., Pavel S. UVA-1 cold light therapy in the treatment of atopic dermatitis: 61 patients treated in the Leiden University Medical Center. Photodermatol. Photoimmunol. Photomed. 2005; 21(2): 93—6.
  27. Dawe R.S. Ultraviolet A1 phototherapy. Br. J. Dermatol. 2003; 148(4): 626—37.
  28. Godar D.E. UVA1 radiation triggers two different final apoptotic pathways. J. Invest. Dermatol. 1999; 112(1): 3—12.
  29. Guhl S., Hartmann K., Tapkenhinrichs S., Smorodchenko A., Grützkau A., Henz B.M. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. J. Invest. Dermatol. 2003; 121(4): 837—44.
  30. Mang R., Krutmann J. UVA-1 phototherapy. Photodermatol. Photoimmunol. Photomed. 2005; 21(2): 103—8.
  31. York N.R., Jacobe H.T. UVA1 phototherapy: a review of mechanism and therapeutic application. Int. J. Dermatol. 2010; 49(6): 623—30.
  32. Kreuter A., Hyun J., Skrygan M., Sommer A., Bastian A., Altmeyer P. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br. J. Dermatol. 2006; 155(3): 600—7.
  33. Kronauer C., Eberlein-Konig B., Ring J., Behrendt H. Influence of UVB, UVA and UVA1 irradiation on histamine release from human basophils and mast cells in vitro in the presence and absence of antioxidants. Photochem. Photobiol. 2003; 77(5): 531—4.
  34. Olisova O. Ju. Modern apporoach to psoriasis treatment (Sovremennye podhody k vedeniju bol’nyh psoriazom). Russkij medicinskij zhurnal. 2004; 4: 182—5.
  35. Nijsten T.E., Stern R.S. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J. Invest. Dermatol. 2003; 121(2): 252—8.
  36. De Fabo E.C., Noonan F.P., Fears T., Merlino G. Ultraviolet B but not ultraviolet A radiation initiates melanoma. Cancer Res. 2004; 64(18): 6372—6.
  37. Budden T., Bowden N.A. The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis. Int. J. Mol. Sci. 2013; 14(1): 1132—51.
  38. Suh K.S., Kang J.S., Baek J.W., Kim T.K., Lee J.W., Jeon Y.S. Efficacy of ultraviolet A1 phototherapy in recalcitrant skin diseases. Ann. Dermatol. 2010; 22(1): 1—8.
  39. Dittmar H.C., Pflieger D., Schopf E., Simon J.C. UVA1 phototherapie. Pilot study of dose finding in acute exacerbated atopic dermatitis. Hautarzt. 2001; 52(5): 423—7.
  40. von Kobyletzki G., Pieck C., Hoffmann K., Freitag M., Altmeyer≈P. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J. Am. Acad. Dermatol. 1999; 41(6): 931—7.
  41. Musson R.E., Hensbergen P.J., Westphal A.H., Temmink W.P., Deelder A.M., van Pelt J. UVA1 radiation inhibits calcineurin through oxidative damage mediated by photosensitization. Radic. Biol. Med. 2011; 50(10): 1392—9.
  42. Gambichler T., Othlinghaus N., Tomi N.S., Holland-Letz T., Boms S., Skrygan M., et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br. J. Dermatol. 2009; 160(3): 652—8.
  43. de Kort W.J., van Weelden H. Bath psoralen-ultraviolet A therapy in atopic eczema. J. Eur. Acad. Dermatol. Venereol. 2000; 14(3): 172—4.
  44. Seeber A., Tzaneva S., Schwaiger M., Hönigsmann H., Tanew A. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J. Am. Acad. Dermatol. 2001; 45(4): 503—7.
  45. Majoie I.M., Oldhoff J.M., van Weelden H., Laaper-Ertmann M., Bousema M.T., Sigurdsson V. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 2009; 60(1): 77—84.
  46. Tzaneva S., Kittler H., Holzer G., Reljic D., Weber M., Hoënigsmann H., Tanew A. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br. J. Dermatol. 2010; 162(3): 655—60.
  47. Kowalzick L., Kleinheinz A., Weichenthal M., Neuber K., Kohler I., Grosch J. Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm. Venereol. 1995; 75(1): 43—5.

版权所有 © Eco-Vector, 2013


 


##common.cookie##